Posted by Clinical Lab Products | Aug 28, 2009 | Cancer, Miscellaneous |
Gen-Probe Incorporated (NASDAQ: GPRO) announced that the Company has begun a clinical trial intended to secure U.S. regulatory approval of its PROGENSA PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy.
Read MorePosted by Clinical Lab Products | Aug 24, 2009 | Cancer, Miscellaneous |
AMDL Inc announces the inauguration of AMDL Diagnostics Inc (ADI), a new wholly-owned subsidiary that will focus on the research, development, manufacture and international sales of Onko-SureAMDL’s proprietary, regulatory approved in vitro diagnostic (IVD) cancer test.
Read MorePosted by Clinical Lab Products | Aug 3, 2009 | Cancer, Miscellaneous |
DxS Ltd announces it is working closely with AstraZeneca to make available a companion diagnostic for use with IRESSA (gefitinib), AstraZenecas treatment for non small cell lung cancer (NSCLC).
Read MorePosted by Clinical Lab Products | Jul 15, 2009 | Cancer, Molecular Diagnostics |
Abbott and GlaxoSmithKline (GSK) will develop an automated molecular diagnostic test intended to screen non-small cell lung cancer (NSCLC) tumors for expression of the MAGE-A3 antigen.
Read MorePosted by Clinical Lab Products | Jul 9, 2009 | Cancer, Miscellaneous |
AMDL Inc a US-based pharmaceutical company with major operations in China, announced today the launch of a new brand name for its DR-70 (FDP) in vitro diagnostic cancer test. With today’s announcement, AMDL will manufacture, market, and sell DR-70 under the brand name Onko-Sure.
Read More